[go: up one dir, main page]

SG11201403727YA - Piperazinyl derivatives for the treatment of cancer - Google Patents

Piperazinyl derivatives for the treatment of cancer

Info

Publication number
SG11201403727YA
SG11201403727YA SG11201403727YA SG11201403727YA SG11201403727YA SG 11201403727Y A SG11201403727Y A SG 11201403727YA SG 11201403727Y A SG11201403727Y A SG 11201403727YA SG 11201403727Y A SG11201403727Y A SG 11201403727YA SG 11201403727Y A SG11201403727Y A SG 11201403727YA
Authority
SG
Singapore
Prior art keywords
cancer
treatment
piperazinyl derivatives
piperazinyl
derivatives
Prior art date
Application number
SG11201403727YA
Inventor
Denis Carniato
Jean-François Briand
Mathieu Gutmann
Olivier Busnel
Cécile Bougeret
Benoit Deprez
Karine Jaillardon
Original Assignee
Pitty Marc Henry
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pitty Marc Henry filed Critical Pitty Marc Henry
Publication of SG11201403727YA publication Critical patent/SG11201403727YA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201403727YA 2011-12-30 2012-12-28 Piperazinyl derivatives for the treatment of cancer SG11201403727YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1162586A FR2985256B1 (en) 2011-12-30 2011-12-30 PIPERAZINYL DERIVATIVES FOR THE TREATMENT OF CANCERS
PCT/EP2012/077059 WO2013098393A1 (en) 2011-12-30 2012-12-28 Piperazinyl derivatives for the treatment of cancer

Publications (1)

Publication Number Publication Date
SG11201403727YA true SG11201403727YA (en) 2014-09-26

Family

ID=47470025

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201403727YA SG11201403727YA (en) 2011-12-30 2012-12-28 Piperazinyl derivatives for the treatment of cancer

Country Status (17)

Country Link
US (1) US9321778B2 (en)
EP (1) EP2797898B9 (en)
JP (1) JP6105625B2 (en)
KR (1) KR102086732B1 (en)
CN (1) CN104053648B (en)
AU (1) AU2012360815B2 (en)
BR (1) BR112014015991B1 (en)
CA (1) CA2859721C (en)
ES (1) ES2606289T3 (en)
FR (1) FR2985256B1 (en)
HU (1) HUE030951T2 (en)
IL (1) IL233414A (en)
PL (1) PL2797898T3 (en)
RU (1) RU2629115C2 (en)
SG (1) SG11201403727YA (en)
WO (1) WO2013098393A1 (en)
ZA (1) ZA201405068B (en)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10358539A1 (en) * 2003-12-15 2005-07-07 Merck Patent Gmbh carboxamide
US20060058296A1 (en) * 2003-12-24 2006-03-16 Scios, Inc. Treatment of osteolytic lesions associated with multiple myeloma by inhibition of p38 map kinase
MXPA06012394A (en) * 2004-04-30 2007-01-31 Bayer Pharmaceuticals Corp Substituted pyrazolyl urea derivatives useful in the treatment of cancer.
US7615556B2 (en) * 2006-01-27 2009-11-10 Bristol-Myers Squibb Company Piperazinyl derivatives as modulators of chemokine receptor activity
WO2008135786A1 (en) * 2007-05-04 2008-11-13 Astrazeneca Ab Amino-thiazolyl- pyrimidine derivatives and their use for the treatment of cancer
FR2932483A1 (en) * 2008-06-13 2009-12-18 Cytomics Systems COMPOUNDS USEFUL FOR THE TREATMENT OF CANCERS.
WO2010091164A1 (en) * 2009-02-06 2010-08-12 Exelixis, Inc. Inhibitors of glucosylceramide synthase
UY32648A (en) * 2009-05-21 2010-12-31 Astrazeneca Ab NEW DERIVATIVES OF PYRIMIDINE AND ITS USE IN THE TREATMENT OF DISEASES
WO2012009678A1 (en) * 2010-07-16 2012-01-19 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their method of use
US20130071328A1 (en) 2011-03-22 2013-03-21 University Of Southern California Propynoic Acid Carbamoyl Methyl-Amides and Pharmaceutical Compositions and Methods Based Thereon

Also Published As

Publication number Publication date
EP2797898B1 (en) 2016-09-14
FR2985256A1 (en) 2013-07-05
PL2797898T3 (en) 2017-03-31
WO2013098393A1 (en) 2013-07-04
HUE030951T2 (en) 2017-06-28
JP2015505308A (en) 2015-02-19
CN104053648B (en) 2016-09-28
EP2797898A1 (en) 2014-11-05
CN104053648A (en) 2014-09-17
IL233414A (en) 2015-11-30
NZ627149A (en) 2015-08-28
AU2012360815A1 (en) 2014-07-31
BR112014015991B1 (en) 2022-11-16
CA2859721A1 (en) 2013-07-04
HK1202118A1 (en) 2015-09-18
FR2985256B1 (en) 2016-03-04
US20140356360A1 (en) 2014-12-04
KR20140117456A (en) 2014-10-07
CA2859721C (en) 2020-01-07
AU2012360815B2 (en) 2017-02-02
US9321778B2 (en) 2016-04-26
BR112014015991A8 (en) 2017-07-04
KR102086732B1 (en) 2020-03-09
BR112014015991A2 (en) 2017-06-13
RU2629115C2 (en) 2017-08-24
JP6105625B2 (en) 2017-03-29
ES2606289T3 (en) 2017-03-23
RU2014131001A (en) 2016-02-20
EP2797898B9 (en) 2021-05-26
ZA201405068B (en) 2015-11-25
IL233414A0 (en) 2014-08-31

Similar Documents

Publication Publication Date Title
IL235726A0 (en) Pyrimidine compounds for the treatment of cancer
IL231835A0 (en) Pyrrolopyrimidine compounds for the treatment of cancer
IL232530A0 (en) Combination treatment of cancer
GB201115711D0 (en) Phyto-cannabinoids for use in the treatment of cancer
EP2751267A4 (en) Methods for the treatment of breast cancer
PT2804599T (en) Combination therapy for the treatment of cancer
EP2903644A4 (en) Treatment of cancer
IL228430A0 (en) Treatment of cancer
GB201217892D0 (en) Treatment of cancer
IL275636A (en) Therapeutic combination for the treatment of cancer
PL2817286T3 (en) Kinase inhibitors for the treatment of cancer
PL2855475T3 (en) Alpha-carbolines for the treatment of cancer
IL233493A (en) Imidazopyridine derivatives for the treatment of cancer
IL236870B (en) Hydroxystatin derivatives for the treatment of arthrosis
ZA201405068B (en) Piperazinyl derivatives for the treatment of cancer
GB201217890D0 (en) Treatment of cancer
EP2882419A4 (en) Methods for treatment of cancer using lipoplatin
HUE048942T2 (en) Anthracyline derivatives for treating tumor diseases
IL233495A0 (en) Combination therapy for the treatment of cancer
GB201121791D0 (en) Combination treatment of cancer
GB201121783D0 (en) Treatment of cancer
AU2012901199A0 (en) Kinase inhibitors for the Treatment of Cancer
AU2012905667A0 (en) Vaccines for treatment of cancer
GB201208296D0 (en) Treatment of cancer